ReviewCell proliferation2017
CCAT2: A novel oncogenic long non-coding RNA in human cancers.
Review in Cell proliferation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Overexpression of LncRNA GHET1 predicts an unfavourable survival and clinical parameters of patients in various cancers.Journal of cellular and molecular medicine · 2019Pooled it
- Harnessing the LncRNA CCAT2 role in gastric cancer: from molecular insights to clinical implications.Cancer cell international · 2026Review
- LncRNA CCAT2 role in female-related cancer progression and diagnosis: a comprehensive review.Clinical and experimental medicine · 2026Review
- Associations of CCAT2 gene polymorphisms with neuroblastoma susceptibility in children from Jiangsu province.European journal of medical research · 2025Article
- The CCAT2 enigma: pioneering insights into colorectal cancer pathophysiology and therapeutic innovation.Cancer cell international · 2025Review
- Review
- CCAT2 role in gastrointestinal cancer progression and metastasis: a novel target for therapeutic strategies.Clinical and experimental medicine · 2025Review
- LncRNA CCAT2 Knockdown Alleviates Pressure Overload or Ang II-Induced Cardiac Hypertrophy Via Disruption of the Wnt/β-Catenin Signaling.Arquivos brasileiros de cardiologia · 2024Article
- The Role of Long Noncoding RNAs (lncRNAs) in Esophageal Cancer Therapy Resistance and Metastasis.Biomedicines · 2024Review
- Review
- Long Non-Coding RNA CCAT2 and Pathological Cardiac Remodeling.Arquivos brasileiros de cardiologia · 2024Article
- Tectorigenin Inhibits Glycolysis-induced Cell Growth and Proliferation by Modulating LncRNA CCAT2/miR-145 Pathway in Colorectal Cancer.Current cancer drug targets · 2024Article
- LncRNA CCAT2, involving miR-34a/TGF-β1/Smad4 signaling, regulate hepatic stellate cells proliferation.Scientific reports · 2022Article
- Gemini Curcumin Suppresses Gastric Cancer AGS Cell Proliferation Through Modulation ofTurkish journal of pharmaceutical sciences · 2022Article
- Article
- Long noncoding RNA CCAT2 reduces chemosensitivity to 5-fluorouracil in breast cancer cells by activating the mTOR axis.Journal of cellular and molecular medicine · 2022Article
- Long non-coding RNA CCAT2 drives the growth of laryngeal squamous cell carcinoma via regulating YAP activity.Human cell · 2021Article
- CCAT2 enhances autophagy-related invasion and metastasis via regulating miR-4496 and ELAVL1 in hepatocellular carcinoma.Journal of cellular and molecular medicine · 2021Article
- The emerging regulatory roles of long non-coding RNAs implicated in cancer metabolism.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Review
- Decoding LncRNAs.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer-associated transcript 2 (CCAT2) was originally identified as an oncogenic long non-coding RNA in colorectal cancer. Since its discovery, the oncogenic role of CCAT2 has been increasingly demonstrated in human cancers. In this connection, CCAT2 upregulation is frequently reported and very often associated with tumour progression and poor clinical outcomes. Functionally, knockdown of CCAT2 could induce cancer cell apoptosis and suppress cell proliferation and invasiveness, suggesting that CCAT2 might be a therapeutic target. The present review summarized current literature concerning the expression and functional role of CCAT2 in human malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.